• Intrasense is pursuing the sale of its Myrian business, with all H1 2026 revenue generated from that perimeter.
• The potential divestment would shift the group’s focus to DUOnco AI oncology products developed with Guerbet.
• H1 2026 revenue fell 59.3% to EUR 646,000, reflecting timing slippage in maintenance renewals and license orders tied to Myrian.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intrasense SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.